ClinVar Miner

Submissions for variant NM_000179.3(MSH6):c.3261del (p.Phe1088fs)

dbSNP: rs267608078
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 28
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
International Society for Gastrointestinal Hereditary Tumours (InSiGHT) RCV000074830 SCV000108041 pathogenic Lynch syndrome 2013-09-05 reviewed by expert panel research Coding sequence variation resulting in a stop codon
GeneDx RCV000202045 SCV000149320 pathogenic not provided 2021-11-18 criteria provided, single submitter clinical testing Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (Lek 2016); Observed in the heterozygous state in patients with Lynch-related cancers consistent with pathogenic variants in this gene (Plaschke 2004, Hampel 2005, Baglietto 2010, Sjursen 2010, Talseth-Palmer 2010, Meric-Bernstam 2016); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; This variant is associated with the following publications: (PMID: 26552419, 26787237, 15872200, 29371908, 20591884, 20028993, 15483016, 20487569, 20587412, 26866578, 27601186, 27486176, 25980754, 10508506, 22734033, 26681312, 28528517, 26318770, 30730459, 30322717, 30093976, 31447099, 31845022, 31921681, 32832836, 32042422, 17557300, 32719484, 30787465, 33087929)
Ambry Genetics RCV000115411 SCV000187451 pathogenic Hereditary cancer-predisposing syndrome 2021-09-17 criteria provided, single submitter clinical testing The c.3261delC pathogenic mutation, located in coding exon 5 of the MSH6 gene, results from a deletion of one nucleotide at nucleotide position 3261, causing a translational frameshift with a predicted alternate stop codon (p.F1088Sfs*2). This mutation has been reported in multiple hereditary non-polyposis colorectal cancer (HNPCC)/Lynch syndrome families; several whose LS-associated tumors demonstrating high microsatellite instability and/or loss of MSH6 staining by immunohistochemistry (IHC) (Wijnen J et al. Nat. Genet. 1999 Oct;23:142-4; Kets CM et al. Br J Cancer, 2006 Dec;95:1678-82; Devlin LA et al. Ulster Med J, 2008 Jan;77:25-30; Talseth-Palmer BA et al. Hered. Cancer Clin. Pract. 2010 May;8:5; van der Post RS et al. J. Med. Genet. 2010 Jul;47:464-70; Bonnet D et al. Dig Liver Dis, 2012 Jun;44:515-22; Sjursen W et al. Mol Genet Genomic Med, 2016 Mar;4:223-31; Lagerstedt-Robinson K et al. Oncol Rep. 2016 Nov;36(5):2823-2835; Chan GHJ et al. Oncotarget, 2018 Jul;9:30649-30660; Carter NJ et al. Gynecol Oncol, 2018 12;151:481-488; Matejcic M et al. JCO Precis Oncol, 2020 Jan;4:32-43; Ylmaz A et al. Int J Colorectal Dis, 2020 Feb;35:351-353). This mutation has also been reported in the homozygous state as well as compound heterozygous with a second mutation in MSH6 in several patients with Constitutional Mismatch Repair Deficiency (CMMRD) syndrome (Auclair J et al. Hum Mutat. 2007 Nov;28(11):1084-90; Xu M et al. Biomed Rep, 2020 Mar;12:134-138; Ando T et al. BMC Gastroenterol, 2021 Aug;21:326). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Invitae RCV000524165 SCV000255262 pathogenic Hereditary nonpolyposis colorectal neoplasms 2024-01-24 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Phe1088Serfs*2) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This premature translational stop signal has been observed in individual(s) with Lynch syndrome (PMID: 10508506, 15483016, 18301448, 20007843, 20028993, 20587412, 20591884, 22734033). ClinVar contains an entry for this variant (Variation ID: 89363). For these reasons, this variant has been classified as Pathogenic.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000202045 SCV000601570 pathogenic not provided 2021-01-05 criteria provided, single submitter clinical testing This variant alters the translational reading frame of the MSH6 mRNA and causes the premature termination of MSH6 protein synthesis. In the published literature, this variant has been reported in individuals affected with a Lynch syndrome associated cancer (PMIDs: 20028993 (2010), 20591884 (2010), 22734033 (2012), 26787237 (2016), 29371908 (2018)) and CMMRD (PMID: 32042422 (2020)). The frequency of this variant in the general population, 0.000014 (4/280876 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is consistent with pathogenicity. Based on the available information, this variant is classified as pathogenic.
Color Diagnostics, LLC DBA Color Health RCV000115411 SCV000685379 pathogenic Hereditary cancer-predisposing syndrome 2023-02-17 criteria provided, single submitter clinical testing This variant deletes 1 nucleotide in exon 5 of the MSH6 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in individuals and families affected with Lynch syndrome, Muir-Torre syndrome, or constitutional mismatch repair deficiency syndrome (PMID: 15236168, 15483016, 17117178, 17557300, 20007843, 20487569, 20587412, 22480969, 22734033, 27064304). This variant has been identified in 1/30714 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of MSH6 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000074830 SCV000695853 pathogenic Lynch syndrome 2016-08-29 criteria provided, single submitter clinical testing Variant summary: The MSH6 c.3261delC (p.Phe1088Serfs) variant results in a premature termination codon, predicted to cause a truncated or absent MSH6 protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g. p.Arg1172fs). One in silico tool predicts a damaging outcome for this variant. This variant was found in 21/120336 control chromosomes at a frequency of 0.0001745, which is approximately equal to the estimated maximal expected allele frequency of a pathogenic MSH6 variant (0.0001421). However, the variant has been reported in many HNPCC patients in the literature in heterozygous state. The variant has also been cited in homozygous and compound heterozygous states in patients with early onset cancer phenotypes (Ilencikova_PedBlodCanc_2011 and Auclair_HumMut_2007, respectively). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic.
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000074830 SCV000711434 pathogenic Lynch syndrome 2019-04-22 criteria provided, single submitter clinical testing The p.Phe1088SerfsX2 variant in MSH6 has been reported in >5 individuals with MSH6-related cancers (Baglietto 2010, Meric-Bernstam 2016), as well as one individual with constitutional mismatch repair deficiency syndrome (CMMRD) who was compound heterozygous for this variant and another MSH6 variant (Lavoine 2015). This variant has been identified in 1/10322 of Ashkenazi Jewish chromosomes by gnomAD (http://gnomad.broadinstitute.org). It is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 1088 and leads to a premature termination codon 2 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Heterozygous loss of function of function of the MSH6 gene is an established disease mechanism in Lynch Syndrome. Furthermore, this variant was classified as Pathogenic on Sept. 5, 2013 by the ClinGen-approved InSiGHT Expert Panel (ClinVar SCV000108041.2). In summary, this variant meets criteria to be classified as pathogenic for Lynch Syndrome in an autosomal dominant manner. ACMG/AMP Criteria applied: PM2, PVS1, PS4_Supporting.
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000202045 SCV000884140 pathogenic not provided 2017-12-18 criteria provided, single submitter clinical testing The MSH6 c.3261delC, p.Phe1088fs variant (rs267608078) is a recurrent alteration in individuals diagnosed with hereditary nonpolyposis colorectal cancer and other familial cancers (Baglietto 2010, Lavoine 2015, Tavakkol 2012, van der Post 2010, Wijnen 1999). It is classified as pathogenic in ClinVar (Variation ID: 89363), and observed once in the Genome Aggregation Database general population database (1/30714 alleles). The variant introduces a frameshift, and is predicted to result in a truncated protein or an absent transcript. Based on the above information, the variant is classified as pathogenic. References: Baglietto L et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst. 2010; 102(3):193-201. Lavoine N et al. Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort. J Med Genet. 2015; 52(11):770-8. Tavakkol Z et al. Germline mutation in MSH6 associated with multiple malignant neoplasms in a patient With Muir-Torre syndrome. J Clin Oncol. 2012; 30(22):e195-8. van der Post R et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet. 2010; 47(7):464-70. Wijnen J et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet. 1999; 23(2):142-4.
CeGaT Center for Human Genetics Tuebingen RCV000202045 SCV001250452 pathogenic not provided 2023-08-01 criteria provided, single submitter clinical testing MSH6: PVS1, PS4:Moderate
Clinical Genetics and Genomics, Karolinska University Hospital RCV000202045 SCV001449559 pathogenic not provided 2014-09-01 criteria provided, single submitter clinical testing
Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden RCV000202045 SCV002010094 pathogenic not provided 2021-11-03 criteria provided, single submitter clinical testing
Revvity Omics, Revvity Omics RCV000202045 SCV002017593 pathogenic not provided 2024-01-04 criteria provided, single submitter clinical testing
Mendelics RCV001762178 SCV002517643 pathogenic Endometrial carcinoma 2022-05-04 criteria provided, single submitter clinical testing
MGZ Medical Genetics Center RCV001824596 SCV002580158 pathogenic Lynch syndrome 5 2022-05-30 criteria provided, single submitter clinical testing
Genetics and Molecular Pathology, SA Pathology RCV000074830 SCV002761956 pathogenic Lynch syndrome 2019-07-24 criteria provided, single submitter clinical testing
Institute of Human Genetics, University of Leipzig Medical Center RCV001762178 SCV002765104 pathogenic Endometrial carcinoma 2022-12-06 criteria provided, single submitter clinical testing _x000D_ Criteria applied: PVS1, PS4_MOD
Fulgent Genetics, Fulgent Genetics RCV002498358 SCV002810377 pathogenic Endometrial carcinoma; Lynch syndrome 5; Mismatch repair cancer syndrome 3 2021-12-14 criteria provided, single submitter clinical testing
Institute of Human Genetics, University of Leipzig Medical Center RCV001824596 SCV004100797 pathogenic Lynch syndrome 5 2023-09-14 criteria provided, single submitter clinical testing Criteria applied: PVS1,PS4,PM2_SUP
Myriad Genetics, Inc. RCV001824596 SCV004187417 pathogenic Lynch syndrome 5 2023-08-22 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.
Baylor Genetics RCV001762178 SCV004195755 pathogenic Endometrial carcinoma 2023-05-30 criteria provided, single submitter clinical testing
OMIM RCV000009499 SCV000029717 pathogenic Mismatch repair cancer syndrome 3 2007-11-01 no assertion criteria provided literature only
Mayo Clinic Laboratories, Mayo Clinic RCV000202045 SCV000257247 pathogenic not provided no assertion criteria provided clinical testing
Department of Pathology and Laboratory Medicine, Sinai Health System RCV001353984 SCV000592632 pathogenic Carcinoma of colon no assertion criteria provided clinical testing The p.Phe1088SerfsX2 variant was identified in 15 of 6554 proband chromosomes (frequency: 0.002) from individuals or families with Lynch syndrome (Bonadona 2011, Devlin 2008, Hampel 2005, Hendriks 2004, Overbeek 2007, Plaschke 2004, Sjursen 2010). The variant was also identified in dbSNP (ID: rs267608078) “With pathogenic allele”, Clinvitae database (2x as pathogenic), InSiGHT Colon Cancer Gene Variant Database (24x as pathogenic), the ClinVar database (classified as a pathogenic variant by an expert panel), GeneInsight COGR database 1x and UMD (27x as a causal variant). The p.Phe1088SerfsX2 deletion variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 1088 and leads to a premature stop codon at position 1089. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the MSH6 gene are an established mechanism of disease in Lynch syndrome and this is the type of variant expected to cause the disorder. In summary, based on the above information, this variant meets our laboratory’s criteria to be classified as pathogenic.
Constitutional Genetics Lab, Leon Berard Cancer Center RCV001249957 SCV001423971 pathogenic Lynch-like syndrome 2019-07-01 no assertion criteria provided clinical testing
GenomeConnect, ClinGen RCV001824596 SCV002075254 not provided Lynch syndrome 5 no assertion provided phenotyping only Variant interpreted as Pathogenic and reported on 03-09-2020 by Lab or GTR ID 1197. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant.
Laboratory for Genotyping Development, RIKEN RCV003162476 SCV002758318 pathogenic Gastric cancer 2021-07-01 no assertion criteria provided research
CZECANCA consortium RCV001762178 SCV003804329 pathogenic Endometrial carcinoma 2023-02-21 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.